NOXXON Pharma N.V. announced the collaboration with three additional clinical sites to increase recruitment capacity for the Phase I/II brain cancer study of NOX-A12 plus radiotherapy, as a measure to ensure the timely completion of the study under the current challenging conditions posed by the COVID-19 pandemic.
[NOXXON Pharma N.V.]
6807162 nan items 1 apa default asc 1
Biotechnology company NOXXON Pharma N.V. announced that all three patients of the second dose cohort have been enrolled into the brain cancer clinical trial testing CXCL12 inhibitor, NOX-A12, and have already received the planned initial treatment. The Phase I/II clinical study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external beam radiotherapy in newly diagnosed brain cancer patients.
[Noxxon Pharma N.V.]
6630899 nan items 1 apa default asc 1
The authors showed that Mlc1 was expressed in human stem-like glioblastoma (GBM) cells and was linked to the development of primary and recurrent GBM.
6445212 5TG6CSCH items 1 apa default asc 1
Immunomedics, Inc.announced that Trodelvy™ delivered 150-fold and 40-fold the 50% inhibitory concentration of SN-38 for brain metastasis from breast cancer and recurrent glioblastoma, respectively, and produced partial responses in both cohorts of brain cancer patients.
When neural stem cells (NSCs) were implanted 2 mm lateral from the tumor foci, NSCs co-localized with the GBM within seven days. In models of multi-focal disease, NSCs were found to co-localize with multiple tumors, preferentially migrating to tumor foci closest to the site of NSC implantation.
1254621 DHN7GAAP items 1 apa default asc 1
Researchers investigated the potential mechanism linking P2X7R and GM-CSF in the U251 glioblastoma cell line and the therapeutic potential of P2X7R antagonism in this setting.
6445218 37UMNN25 items 1 apa default asc 1
Drill, M., Powell, K. L., Kan, L. K., Jones, N. C., O’Brien, T. J., Hamilton, J. A., & Monif, M. (2020). Inhibition of purinergic P2X receptor 7 (P2X7R) decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in U251 glioblastoma cells. Scientific Reports, 10(1), 14844. https://doi.org/10.1038/s41598-020-71887-x Cite
Investigators highlight the bidirectional communication of glioma cells and tumor-associated immune cells, the inflammatory mediators enabling leukocytes and transplantable MSC migration, and review preclinical and human clinical trials using MSCs as delivery vehicles.
[Mayo Clinic Proceedings]
Two interdisciplinary research teams at the University of Manitoba’s Rady Faculty of Health Sciences have received one-year grants from The Winnipeg Foundation Innovation Fund for cutting-edge projects that will advance research in the areas of brain disease and mother-infant health.
[University of Manitoba]